Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Starts China Trial of GM-CSF Inhibitor for RA

publication date: Aug 19, 2020

Shanghai's I-Mab has dosed the first patient in a Phase Ib trial of plonmarlimab (TJM2) in patients with rheumatoid arthritis (RA) in China. Plonmarlimab is a humanized immunoglobulin G1 (IgG1) antibody. It targets the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), which plays a critical role in autoimmune and inflammatory disease. Neutralizing GM-CSF diminishes inflammatory responses. In the US, a Phase II trial is underway to test TJM2 in patients with cytokine release syndrome caused by COVID-19. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.